MuSK-CAART / Cabaletta Bio - LARVOL DELTA

Clinical and translational findings following MuSK-CAART infusion without preconditioning in patients with Myasthenia Gravis (MuSCAARTesTM trial) (ESGCT 2024) - No abstract available

Clinical • CNS Disorders • Myasthenia Gravis

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Cabaletta Bio | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Myasthenia Gravis

Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. (PubMed, Nat Biotechnol) - "Specific off-target interactions of MuSK-CAART were not identified in vivo, in primary human cell screens or by high-throughput human membrane proteome array. These data contributed to an investigational new drug application and phase 1 clinical study design for MuSK-CAART for the treatment of MuSK autoantibody-positive MG."

Journal • CNS Disorders • Immunology • Myasthenia Gravis • TNFRSF9

Open-label Study to Determine the Maximum Tolerated Dose of MuSK-CAART for MuSK Myasthenia Gravis (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Cabaletta Bio

New P1 trial • CNS Disorders • Myasthenia Gravis